New insights into the biology of kidney cancer, including those informed by scientific discoveries that earned a Nobel Prize, have led to advances in treatment and increased survival rates, according to a review by UNC Lineberger ...
Aug 28, 2024
0
0
Most tumors release various signaling molecules to support their incessant growth, invasion, and metastasis. Some of these molecules, known as tumor angiogenic factors (TAF), are able to stimulate the formation of new blood ...
Aug 9, 2024
0
0
A team of researchers at the University of Michigan Health Rogel Cancer Center has designed a molecule that impairs signaling mediated by two key drivers of cancer therapy resistance. The design and preclinical evaluation ...
Jul 29, 2024
0
51
A team of researchers from Penn State College of Medicine found a new target for treating diseases associated with human T-cell leukemia virus type 1 (HTLV-1). They determined that blocking a class of enzymes called kinases, ...
Jul 22, 2024
0
27
"Recessive Dystrophic Epidermolysis Bullosa (RDEB) is the worst disease you've probably never heard of," says dermatology researcher Andrew South, Ph.D.. RDEB patients and their families know just how horrible it can be. ...
Jul 17, 2024
0
0
Physician scientists from City of Hope, one of the largest cancer research and treatment organizations in the United States, found that people with metastatic kidney cancer who orally took a live biotherapeutic product called ...
Jun 28, 2024
0
44
Hepatocellular carcinoma (HCC) presents significant challenges due to its high incidence and mortality rates, particularly in China where most patients are diagnosed at intermediate or advanced stages. This limits the applicability ...
Jun 21, 2024
0
0
The U.S. Food and Drug Administration has approved Augtyro (repotrectinib), a next-generation tyrosine kinase inhibitor (TKI), for the treatment of patients with neurotrophic tyrosine receptor kinase (NTRK)-positive locally ...
Jun 21, 2024
0
0
For patients with non-small cell lung cancer with the epidermal growth factor receptor (EGFR) variant, ivonescimab plus chemotherapy improves progression-free survival, according to a study published online May 31 in the ...
Jun 6, 2024
0
18
A medication to treat chronic myeloid leukemia (CML) has shown its potential to become the new frontline therapy for people living with the life-threatening blood cancer.
Jun 4, 2024
0
1
